287 related articles for article (PubMed ID: 32161055)
1. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
Kuwana M; Blair C; Takahashi T; Langley J; Coghlan JG
Ann Rheum Dis; 2020 May; 79(5):626-634. PubMed ID: 32161055
[TBL] [Abstract][Full Text] [Related]
2. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
[TBL] [Abstract][Full Text] [Related]
3. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
Hoeper MM; McLaughlin VV; Barberá JA; Frost AE; Ghofrani HA; Peacock AJ; Simonneau G; Rosenkranz S; Oudiz RJ; White RJ; Miller KL; Langley J; Harris JHN; Blair C; Rubin LJ; Vachiery JL
Lancet Respir Med; 2016 Nov; 4(11):894-901. PubMed ID: 27745818
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension.
White RJ; Vonk-Noordegraaf A; Rosenkranz S; Oudiz RJ; McLaughlin VV; Hoeper MM; Grünig E; Ghofrani HA; Chakinala MM; Barberà JA; Blair C; Langley J; Frost AE
Respir Res; 2019 Sep; 20(1):208. PubMed ID: 31511080
[TBL] [Abstract][Full Text] [Related]
5. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
Vachiéry JL; Galiè N; Barberá JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Blair C; Miller KL; Langley J; Rubin LJ;
J Heart Lung Transplant; 2019 Feb; 38(2):194-202. PubMed ID: 30522722
[TBL] [Abstract][Full Text] [Related]
6. Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension.
Hatano M; Abe K; Koike G; Takahashi T; Tunmer G; Kiely DG
Int Heart J; 2022; 63(1):99-105. PubMed ID: 35095084
[TBL] [Abstract][Full Text] [Related]
7. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
8. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial.
McLaughlin VV; Vachiery JL; Oudiz RJ; Rosenkranz S; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Peacock AJ; Simonneau G; Rubin LJ; Blair C; Langley J; Hoeper MM;
J Heart Lung Transplant; 2019 Dec; 38(12):1286-1295. PubMed ID: 31648845
[TBL] [Abstract][Full Text] [Related]
9. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Vachiery JL; Grünig E; Oudiz RJ; Vonk-Noordegraaf A; White RJ; Blair C; Gillies H; Miller KL; Harris JH; Langley J; Rubin LJ;
N Engl J Med; 2015 Aug; 373(9):834-44. PubMed ID: 26308684
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
[TBL] [Abstract][Full Text] [Related]
11. Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score.
Frost AE; Hoeper MM; Barberá JA; Vachiery JL; Blair C; Langley J; Rubin LJ
J Heart Lung Transplant; 2018 Dec; 37(12):1410-1417. PubMed ID: 30209017
[TBL] [Abstract][Full Text] [Related]
12. Ambrisentan: a review of its use in pulmonary arterial hypertension.
Rivera-Lebron BN; Risbano MG
Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH): Recent and advanced data.
Thoreau B; Mouthon L
Autoimmun Rev; 2024 Apr; 23(4):103506. PubMed ID: 38135175
[TBL] [Abstract][Full Text] [Related]
14. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study).
Pan Z; Marra AM; Benjamin N; Eichstaedt CA; Blank N; Bossone E; Cittadini A; Coghlan G; Denton CP; Distler O; Egenlauf B; Fischer C; Harutyunova S; Xanthouli P; Lorenz HM; Grünig E
Arthritis Res Ther; 2019 Oct; 21(1):217. PubMed ID: 31655622
[TBL] [Abstract][Full Text] [Related]
15. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.
Galiè N; Denton CP; Dardi F; Manes A; Mazzanti G; Li B; Varanese L; Esler A; Harmon C; Palazzini M
Int J Cardiol; 2017 May; 235():67-72. PubMed ID: 28279499
[TBL] [Abstract][Full Text] [Related]
16. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension.
D'Alto M; Badagliacca R; Lo Giudice F; Argiento P; Casu G; Corda M; Correale M; Ghio S; Greco A; Lattanzio M; Mercurio V; Paciocco G; Papa S; Prediletto R; Romeo E; Russo MG; Tayar A; Vitulo P; Vizza CD; Golino P; Naeije R
J Heart Lung Transplant; 2020 Dec; 39(12):1389-1397. PubMed ID: 32933828
[TBL] [Abstract][Full Text] [Related]
18. Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study.
Pestaña-Fernández M; Rubio-Rivas M; Tolosa-Vilella C; Guillén-Del-Castillo A; Freire M; Vargas-Hitos JA; Todolí-Parra JA; Rodríguez-Carballeira M; Marín-Ballvé A; Espinosa G; Colunga-Argüelles D; Ortego-Centeno N; Trapiella-Martínez L; Carbonell-Muñoz C; Pla-Salas X; Perales-Fraile I; Corbella X; Fonollosa-Pla V; Simeón-Aznar CP;
J Rheumatol; 2020 Jan; 47(1):89-98. PubMed ID: 30770503
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment.
Cansu DÜ; Korkmaz C
Clin Rheumatol; 2023 Oct; 42(10):2601-2610. PubMed ID: 36396789
[TBL] [Abstract][Full Text] [Related]
20. Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.
Abston E; Hon S; Lawrence R; Berman J; Govender P; Farber HW
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):234-238. PubMed ID: 33093789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
